*T-cell therapy, that is genetically engineered T-cells, is a valid modality of cancer treatment.  Porter et al updated their finding at the ASH describing response rate in refractory CLL and ALL.  Patients were given a lentiviral vector that expressed a chimeric antigen receptor "with specificity for the B cell Antigen CD19 paired with CD137 and CD3-zeta." (hemonc today) some of the reported results where positively dramatic.
The experience with MAGE 11 for treatment refractory melanoma did not go so well.

Melanoma Antigen Gene Protein MAGE-11 Regulates Androgen Receptor 

What you pick to attack should not be in the brain (attack to the brain by T cell is likely), and involving a "crazy gene" the like of Androgen Receptor will have many unexpected consequences.  patient died with coma and seizures!   T-cell tissue penetration is bound to occur because it is what T cell do so your task is to pick the receptor carefully!

and don't go out there and pick p300, a potent and ubiquitous transcriptional regulator, because it is Ubiquitous!  Tissue specificity as done above in Hematologic malignancies would be more appropriate!
-----------------------------------------------------------------------------------------------

NOW A BIT OF GOOD NEWS

Infusion of Autologous dendritic cell Immunotherapy  (AGS-003) given with SUNITINIB extended survival in Metastatic Renal cell cancer!   Think Immunotherapy when the going get tough we told recently... congrats to NC researcher to have proven the point!   Follow this principle in tough Myeloma cases.  May be drendritic cell infusion will work in Myeloma!